Madison Vaccines Incorporated (MVI) is a clinical stage biopharmaceutical company focused on advancing innovative therapies for prostate cancer.
MVI is working toward a future where men with recurrent prostate cancer will live longer and healthier lives as spouses, fathers and grandfathers.
MVI is now uniquely positioned to achieve this with product-candidates in three distinct stages of prostate cancer from pre-metastatic, to the start of metastases, to late-stage, castrate-resistant disease. We believe our products can make a meaningful difference in treating this disease.
MVI is developing plasmid DNA immunotherapy for prostate cancer patients.
These vaccines are readily manufactured, stable, and are administered with a simple injection. We target patients with the highest risk of developing bone or other metastases after their initial therapy.
MVI DNA vaccines represent discoveries made in the laboratory of Dr. Douglas McNeel at the University of Wisconsin, and licensed to MVI.
MVI-816 is a plasmid DNA vaccine targeting prostatic acid phosphatase (PAP), a well-defined prostate antigen suitable for prostate cancer vaccines. MVI-816 is currently progressing in a randomized, placebo controlled Phase 2 trial in non-metastatic prostate cancer.
MVI-816 is also in a combination trial with a PPD-1 inhibitor for late-stage prostate cancer.
A second vaccine, MVI-118 , is in a Phase 1 clinical trial in men with metastatic prostate cancer who are initiating androgen deprivation therapy (ADT). MVI-118 targets the human androgen receptor, the critical biological target responsible for driving prostate cancer progression and, in many cases, resistance to current therapies.